Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of ASCVD

A 10-year risk percentage looks like a precise number. This AHA/ACC special report is, in effect, an honest account of how imprecise that number really is — and what to do about it.

It is the companion piece to the 2018 cholesterol guideline, and its subject is the Pooled Cohort Equations, the calculator that turns age, blood pressure, cholesterol, and a few other inputs into an estimate of cardiovascular risk. The report is candid that the equations were derived largely from older cohorts and can both over- and under-estimate risk in specific groups. Its remedy is a two-step refinement: first, layer in risk-enhancing factors — a family history of premature disease, persistently high LDL, chronic inflammatory conditions, elevated lipoprotein(a) — that the calculator misses; and second, when the decision is still genuinely uncertain, measure coronary artery calcium to see whether disease is actually present.

This is the document’s quiet importance. It moves the field from a single calculated number toward looking directly at the artery. A CAC score of zero can justify deferring a statin in a borderline patient; a high score can reclassify someone the calculator called low-risk into someone who plainly needs treatment.

The acknowledged gap is that no outcomes trial had yet tested whether managing patients by these tools — rather than treating everyone above a threshold — actually changes outcomes. The strategy is built on validation and reclassification data, not on a randomized endpoint.

We rate the evidence strong. It is a careful, practical synthesis that takes the limitations of risk scoring seriously and points toward the more direct question: not what a patient’s estimated risk is, but whether the disease is there to be found.